Dechra Pharmaceuticals Return On Equity vs. Price To Sales

DPHAYDelisted Stock  USD 93.78  0.00  0.00%   
Based on Dechra Pharmaceuticals' profitability indicators, Dechra Pharmaceuticals PLC may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Dechra Pharmaceuticals' ability to earn profits and add value for shareholders.
For Dechra Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Dechra Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Dechra Pharmaceuticals PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Dechra Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Dechra Pharmaceuticals PLC over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Please note, there is a significant difference between Dechra Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dechra Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dechra Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Dechra Pharmaceuticals Price To Sales vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Dechra Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Dechra Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Dechra Pharmaceuticals PLC is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in price to sales category among its peers fabricating about  63.05  of Price To Sales per Return On Equity. Comparative valuation analysis is a catch-all model that can be used if you cannot value Dechra Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Dechra Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Dechra Price To Sales vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Dechra Pharmaceuticals

Return On Equity

 = 

Net Income

Total Equity

 = 
0.0896
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Dechra Pharmaceuticals

P/S

 = 

MV Per Share

Revenue Per Share

 = 
5.65 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Dechra Price To Sales Comparison

Dechra Pharmaceuticals is currently under evaluation in price to sales category among its peers.

Dechra Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Dechra Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Dechra Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Dechra Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Dechra Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom. Dechra Pharmaceuticals operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 1699 people.

Dechra Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Dechra Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Dechra Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Dechra Pharmaceuticals' important profitability drivers and their relationship over time.

Use Dechra Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dechra Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dechra Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Dechra Pharmaceuticals Pair Trading

Dechra Pharmaceuticals PLC Pair Trading Analysis

The ability to find closely correlated positions to Dechra Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dechra Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dechra Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dechra Pharmaceuticals PLC to buy it.
The correlation of Dechra Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dechra Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dechra Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dechra Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Dechra Pharmaceuticals position

In addition to having Dechra Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Casinos Thematic Idea Now

Casinos
Casinos Theme
Companies that are related to providing casino-type services across multiple geographical areas. The Casinos theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Casinos Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Other Consideration for investing in Dechra Pink Sheet

If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Equity Valuation
Check real value of public entities based on technical and fundamental data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance